诺维本联合希罗达方案与紫杉醇、顺铂方案治疗晚期乳腺癌的疗效对比

目的:比较诺维本联合希罗达方案(NF方案)和紫杉醇联合顺铂方案(TP方案)治疗晚期乳腺癌的疗效及安全性。方法:将117例经病理证实的晚期乳腺癌患者随机分为两组,第一组66例采用紫杉醇135mg/m~2,第1天静点,顺铂20mg,第2-6天静点,21天为一个周期。第二组51例采用诺维本25mg/m~2,第1,8天静点,希罗达2500mg/m~2,每天2次,连服14天,21天为一个周期。两组均以三个周期为一个疗程,至少接受两个疗程化疗。结果:TP组总有效率为42-4%(28/66);NF组为60.8%(31/51),p<0.05。TP组中位无进展时间7.7个月,中位生存时间为16.6个月。NF组分别为10.3个月和22.1个月,p<0.05。恶心呕吐的发生率NF组明显低于TP组,p<0.05。其余不良反应发生率相近,p>0.05。所有不良反应均能耐受。结论:诺维本联合希罗迭方案疗效较好,可作为晚期乳腺癌首选治疗方案。

Comparison of therapeutic effect between NF plan and TP plan in treatment of advanced breast cancer

Objective:To compare the therapeutic effect and security of NF and TP plans.Methods:A total of 117 patients with advanced breast cancer proved pathologically were divided into NF and TP groups.TP group (66 cases)was received paclitaxel 135 mg/m iv drip d1,cisplatin 20 mg/m~2,iv drip d2-6,the treatment were repeated every 3 weeks.NF group (51 cases)received navelbine 25 mg/m~2,iv drip d1,8,capecitabine 2500 mg/m~2,twice a day,d2-14,the treatment were repeated every 3 weeks,All parents received two cycles of the treatment at least.Results:The total effective rate was 42.4% (28/66)in TP group,but 60.8% (31/51)in NF group,p<0.05. The median time of progression (TTP)was 7.7 months and the median survival time was 16.6 months in the TP group;in the NF group, the TTP was 10.3 months and the median survival time 22.1 months,p<0.05.Nausea was more serious in TP group than in NF group, p<0.05.There was no significant difference in the other side effects between the two groups.All side effects were tolerable.Conclusion: NF plan is still a firstly selected one for patients with advanced breast cancer.